Colorectal Cancer
We recommend
Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene
PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt − wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.
Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for…
Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
In the treatment of metastatic colorectal cancer (mCRC), prognostic factors besides overall…
Articles on this topic
Panitumumab in 1st Line in Older Patients – Results of the PANDA Study
The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab…
Direct Comparison of the Efficacy and Safety of Anti-EGFR Antibodies in the Combined Therapy of Chemotherapy-Refractory Metastatic Colorectal Cancer
The combination of anti-EGFR therapy with irinotecan has brought benefits to patients with…
Impact of Primary Tumor Location and Early Regression on Survival in Patients with Metastatic CRC
Results from recent clinical studies suggest the prognostic significance of the primary tumor…
Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab
At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the…
Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC
As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer…
Testing RAS Gene Mutations in Patients with Colorectal Cancer
Correct identification of the RAS oncogene variant is crucial for deciding the treatment of…
Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer
A pooled analysis of 25 studies with patients in the first line of treatment for metastatic…
FOLFOXIRI and Panitumumab in mCRC Treatment – Improvement in Treatment Response and Metastasis Resectability
For patients with metastatic colorectal cancer (mCRC) who are able to undergo intensive…
Early Cytoreductive Treatment Delays Onset of Symptoms Associated with Metastatic Colorectal Carcinoma
Managing symptoms associated with advanced cancer has a significant impact on patients'…
Meta-analysis of Incidence of Infusion Reactions to Anti-EGFR Antibodies in Patients with mCRC
The application of antibodies against the epidermal growth factor receptor (EGFR),…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Successful Resection of a Rectosigmoid Tumor After Long-term Induction Biochemotherapy – A Case Report
- INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
- Biochemotherapy of Aggressive Rectal Carcinoma – A Case Study from the Czech Republic
- Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
- Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
- Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer
Journal on this topic
Related topic
Interesting links